AMTBio

AMT Bio is creating a new class of biologics to tackle relapse and resistance in solid cancers. Our lead program targets the critical cell populations that drive treatment failure, with the goal of delivering deeper responses and longer periods without disease. In parallel, next-generation approaches are being co-developed with CSIRO to enhance durability, safety, and sovereign manufacturability. We’re building therapies designed not just to shrink tumours, but to change the trajectory of disease.

With local clinical pathways in sight, AMT Bio is advancing bold science into real-world oncology where patients urgently need better, lasting options.

Want to learn more or chat with the team? Reach out to AMT Bio’s team leader, Maree Bilandzic via maree.bilandzic@hudson.org.au

If you would like an introduction – we’re here to help! Contact the ON team via on@csiro.au.